Phase 2a trial of ZPL-3893787 (ZPL-389), a histamine H4 receptor antagonist, for atopic dermatitis

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.